本文關(guān)鍵詞： 乳腺癌 化療 藥物不良反應(yīng) 骨髓抑制　出處：《中國臨床藥理學雜志》2017年19期 　論文類型：期刊論文

【摘要】：目的分析乳腺癌患者化療骨髓抑制與預后的關(guān)系。方法檢索Pub Med,EMbase和Cochrane數(shù)據(jù)庫,進行系統(tǒng)性評價和Meta分析,使用固定效應(yīng)模型或隨機效應(yīng)模型合并風險比(HR)和95%置信區(qū)間(95%CI)。結(jié)果本研究納入9篇研究,共計9103名早期乳腺癌患者。相比于未出現(xiàn)骨髓抑制的患者,骨髓抑制的患者無病生存期(DFS)(HR:0.65,95%CI:0.54~0.79)顯著延長,但總生存期(OS)延長(HR:0.69,95%CI:0.47~1.03)不顯著。但重度骨髓抑制的患者在OS(HR:0.84,95%CI:0.75~0.95)和DFS(HR:0.67,95%CI:0.49~0.92)均顯著獲益。結(jié)論化療誘導的血液學毒性可以作為早期乳腺癌的有效的標志之一,有助于判斷藥效和制定治療決策。
[Abstract]:Objective to analyze the relationship between chemotherapy bone marrow suppression and prognosis in breast cancer patients. Methods Pub Medbase and Cochrane databases were searched for systematic evaluation and Meta analysis. The fixed effect model or stochastic effect model was used to combine the risk ratio (HRR) and the 95% confidence interval (95 CI). Results 9 studies were included in this study. A total of 9103 patients with early breast cancer. Compared with those without bone marrow suppression, the disease-free survival time of patients with bone marrow suppression was 0.65. 95 CI: 0.54 0.79) significantly longer, but the total survival time was prolonged by HR0: 0.69. 95 CI: 0.47 + 1.03) not significantly. But the patients with severe bone marrow suppression were in OS(HR:0.84. 95 CI: 0. 75 and 0. 95) and DFS(HR:0.67. Conclusion Hematological toxicity induced by chemotherapy can be used as one of the effective markers for early breast cancer, which is helpful to judge drug efficacy and make treatment decision.
【作者單位】： 北京大學第一醫(yī)院藥劑科;北京大學醫(yī)學部藥學院藥事管理與臨床藥學系;
【分類號】：R737.9
【正文快照】： (1.北京大學第一醫(yī)院藥劑科,北京100034;2.北京大學醫(yī)學部藥學院藥事管理與臨床藥學系,北京100191)FAN Hong-wei1,2,XIANG Qian1,ZHANG Zhuo1,2,CUI Yi-min1(1.Department of Pharmacy,PekingUniversity First Hospital,Beijing 100034,China;2.Department of PharmacyAdminis，

本文編號：1454034